A Phase III Multicentre, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Nab-Paclitaxel for Chemotherapy-Naive Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer
This randomized Phase III, multicentre, open-label study is designed to evaluate the safety
and efficacy of atezolizumab in combination with carboplatin + nab-paclitaxel compared with
treatment with carboplatin + nab-paclitaxel in chemotherapy-naive participants with Stage IV
non-squamous NSCLC. Participants will be randomized in a 2:1 ratio to Arm A (Atezolizumab +
Nab-Paclitaxel + Carboplatin) or Arm B (Nab-Paclitaxel + Carboplatin).
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society